Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis

BACKGROUND: Trastuzumab is currently the standard treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, it is not recommended for HER2-positive breast cancer patients during pregnancy as it may jeopardize safety of the fetus. Nevertheless, there is evidence t...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Lin-Yu, Hu, Qing-Lin, Zhou, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061001/
https://www.ncbi.nlm.nih.gov/pubmed/33882925
http://dx.doi.org/10.1186/s12905-021-01301-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061001/
https://www.ncbi.nlm.nih.gov/pubmed/33882925
http://dx.doi.org/10.1186/s12905-021-01301-9

Ejemplares similares